$SURG
SurgePays, Inc.

2021 Q4 Form 10-K Financial Statement

#000149315222007663 Filed on March 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020
Revenue $14.16M $51.06M $54.41M
YoY Change 25.25% -6.15% 111.35%
Cost Of Revenue $12.35M $44.89M $51.94M
YoY Change -1.35% -13.57% 129.58%
Gross Profit $1.809M $6.170M $2.469M
YoY Change -249.11% 149.93% -20.86%
Gross Profit Margin 12.78% 12.08% 4.54%
Selling, General & Admin $3.728M $11.40M $11.44M
YoY Change 268.73% -0.33% 7.32%
% of Gross Profit 206.06% 184.82% 463.45%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $180.0K $759.4K $1.173M
YoY Change -39.36% -35.28% 416.18%
% of Gross Profit 9.95% 12.31% 47.53%
Operating Expenses $3.908M $12.16M $12.61M
YoY Change 551.64% -3.58% 15.86%
Operating Profit -$2.099M -$5.993M -$10.15M
YoY Change 15.76% -40.93% 30.61%
Interest Expense $1.092M -$3.780M -$3.162M
YoY Change -215.83% 19.55% 1498.47%
% of Operating Profit
Other Income/Expense, Net -$6.327M -$7.124M $10.00K
YoY Change -71338.5%
Pretax Income -$6.844M -$13.53M -$10.72M
YoY Change 150.06% 26.2% 26.93%
Income Tax
% Of Pretax Income
Net Earnings -$6.844M -$13.53M -$10.72M
YoY Change 150.06% 26.2% 26.93%
Net Earnings / Revenue -48.35% -26.5% -19.71%
Basic Earnings Per Share -$3.09
Diluted Earnings Per Share -$809.6K -$3.088M -$5.023M
COMMON SHARES
Basic Shares Outstanding 4.382M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.284M $6.284M $674.0K
YoY Change 832.27% 832.27% 94.78%
Cash & Equivalents $6.283M $6.284M $674.0K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00 $218.2K
YoY Change -100.0% -100.0% 38.41%
Inventory $4.359M $4.359M $178.3K
Prepaid Expenses
Receivables $3.250M $3.250M $180.5K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.89M $13.89M $1.251M
YoY Change 1010.5% 1010.5% -65.01%
LONG-TERM ASSETS
Property, Plant & Equipment $200.4K $687.1K $605.5K
YoY Change -66.89% 13.49% 19.79%
Goodwill $866.8K
YoY Change
Intangibles $3.433M
YoY Change
Long-Term Investments $443.3K $443.3K $414.6K
YoY Change 6.92% 6.92% 103.54%
Other Assets $0.00 $61.46K
YoY Change -100.0% -7.52%
Total Long-Term Assets $5.608M $5.608M $6.074M
YoY Change -7.68% -7.68% -5.26%
TOTAL ASSETS
Total Short-Term Assets $13.89M $13.89M $1.251M
Total Long-Term Assets $5.608M $5.608M $6.074M
Total Assets $19.50M $19.50M $7.325M
YoY Change 166.21% 166.21% -26.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.992M $7.992M $1.754M
YoY Change 355.71% 355.71% 75.64%
Accrued Expenses $49.35K $49.35K $210.6K
YoY Change -76.56% -76.56% 131.54%
Deferred Revenue
YoY Change
Short-Term Debt $1.680M $1.680M $912.9K
YoY Change 84.06% 84.06% 0.0%
Long-Term Debt Due $4.653M
YoY Change 532.05%
Total Short-Term Liabilities $9.998M $9.998M $15.30M
YoY Change -34.67% -34.67% 116.95%
LONG-TERM LIABILITIES
Long-Term Debt $5.512M $5.512M $1.737M
YoY Change 217.25% 217.25% -73.84%
Other Long-Term Liabilities $438.9K $438.9K $1.010M
YoY Change -56.55% -56.55% 2.05%
Total Long-Term Liabilities $5.951M $5.951M $2.747M
YoY Change 116.59% 116.59% -64.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.998M $9.998M $15.30M
Total Long-Term Liabilities $5.951M $5.951M $2.747M
Total Liabilities $15.95M $15.95M $18.05M
YoY Change -11.65% -11.65% 22.91%
SHAREHOLDERS EQUITY
Retained Earnings -$35.12M
YoY Change
Common Stock $12.06K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.551M $3.551M -$10.73M
YoY Change
Total Liabilities & Shareholders Equity $19.50M $19.50M $7.325M
YoY Change 166.21% 166.21% -26.65%

Cashflow Statement

Concept 2021 Q4 2021 2020
OPERATING ACTIVITIES
Net Income -$6.844M -$13.53M -$10.72M
YoY Change 150.06% 26.2% 26.93%
Depreciation, Depletion And Amortization $180.0K $759.4K $1.173M
YoY Change -39.36% -35.28% 416.18%
Cash From Operating Activities -$8.144M -$15.29M -$4.326M
YoY Change 758.67% 253.4% -33.78%
INVESTING ACTIVITIES
Capital Expenditures -$10.00 -$51.41K -$6.610K
YoY Change -99.59% 677.76% -97.1%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$325.3K $14.96K
YoY Change -2274.6% -92.34%
Cash From Investing Activities -$10.00 -$376.7K $8.350K
YoY Change -99.59% -4611.62% -125.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.79M 21.27M 4.646M
YoY Change 1045.91% 357.94% -28.16%
NET CHANGE
Cash From Operating Activities -8.144M -15.29M -4.326M
Cash From Investing Activities -10.00 -376.7K 8.350K
Cash From Financing Activities 13.79M 21.27M 4.646M
Net Change In Cash 5.648M 5.610M 328.0K
YoY Change 2135.23% 1610.48% -432.71%
FREE CASH FLOW
Cash From Operating Activities -$8.144M -$15.29M -$4.326M
Capital Expenditures -$10.00 -$51.41K -$6.610K
Free Cash Flow -$8.144M -$15.24M -$4.319M
YoY Change 760.9% 252.75% -31.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Notes Receivable Related Parties Noncurrent
NotesReceivableRelatedPartiesNoncurrent
USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
USD
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
USD
CY2021Q4 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
USD
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
USD
CY2021Q4 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
USD
CY2021Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
USD
CY2020 SURG Settlement Expense
SettlementExpense
USD
CY2020 SURG Warrant Modification Expense
WarrantModificationExpense
USD
CY2021 SURG Conversion Of Series C Preferred Stock Into Common Stock
ConversionOfSeriesCPreferredStockIntoCommonStock
USD
CY2021 SURG Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
USD
CY2020 SURG Gain On Forgiveness Of Paycheck Protection Program Loan
GainOnForgivenessOfPaycheckProtectionProgramLoan
USD
CY2020 us-gaap Deconsolidation Gain Or Loss Amount
DeconsolidationGainOrLossAmount
USD
CY2020 SURG Warrant Modification Expense
WarrantModificationExpense
USD
CY2020 SURG Increase Decrease In Accounts Payable And Accrued Expenses Related Party
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty
USD
CY2019Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Options Un Vested And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnVestedAndExercisableNumber
shares
CY2020 us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
USD
CY2021 us-gaap Repayment Of Notes Receivable From Related Parties
RepaymentOfNotesReceivableFromRelatedParties
USD
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
USD
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
USD
CY2020 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
USD
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
USD
CY2021 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
USD
CY2020 SURG Conversion Of Series C Preferred Stock Into Common Stock One
ConversionOfSeriesCPreferredStockIntoCommonStockOne
USD
CY2020 SURG Stock Issued In Settlement Of Liabilities
StockIssuedInSettlementOfLiabilities
USD
CY2020 SURG Conversion Of Debt Into Equity
ConversionOfDebtIntoEquity
USD
CY2020 SURG Termination Of Ecs Rou Lease
TerminationOfEcsRouLease
USD
CY2020 SURG Stock Issued For Acquisition Of Membership Interest In Ecs
StockIssuedForAcquisitionOfMembershipInterestInEcs
USD
CY2020 SURG Reclassifcation Of Accrued Interest Related Party To Note Payable Related Party
ReclassifcationOfAccruedInterestRelatedPartyToNotePayableRelatedParty
USD
CY2020 SURG Deconsolidation Of Subsidiary True Wireless
DeconsolidationOfSubsidiaryTrueWireless
USD
CY2021 us-gaap Stock Issued1
StockIssued1
USD
CY2021 SURG Stock And Warrants Issued Debt Discount
StockAndWarrantsIssuedDebtDiscount
USD
CY2021Q4 SURG Notes Receivable Gross Due In Next Twelve Months
NotesReceivableGrossDueInNextTwelveMonths
USD
CY2021Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
USD
CY2021Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
CY2019Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Options Unvested And Nonexercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndNonexercisable
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
USD
CY2019Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue
USD
CY2019Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable
shares
CY2019Q4 SURG Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercisable
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CY2020 SURG Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value Exercise
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValueExercise
CY2020Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue
USD
CY2020Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue
USD
CY2021Q4 SURG Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAggregateIntrinsicValue
USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
USD
CY2020 SURG Income Tax Reconciliation Tax Effect Of Timing Differences For Income Tax Purposes
IncomeTaxReconciliationTaxEffectOfTimingDifferencesForIncomeTaxPurposes
USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
USD

Files In Submission

Name View Source Status
0001493152-22-007663-index-headers.html Edgar Link pending
0001493152-22-007663-index.html Edgar Link pending
0001493152-22-007663.txt Edgar Link pending
0001493152-22-007663-xbrl.zip Edgar Link pending
ex14-1.htm Edgar Link pending
ex21-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
ex4-4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
form10-k_htm.xml Edgar Link completed
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
surg-20211231.xsd Edgar Link pending
surg-20211231_cal.xml Edgar Link unprocessable
surg-20211231_def.xml Edgar Link unprocessable
surg-20211231_lab.xml Edgar Link unprocessable
surg-20211231_pre.xml Edgar Link unprocessable